Emgality and Aimovig Comparison

Emgality®(galcanezumab-gnlm)	Aimovig®(erenumab-aooe)
Prescription Only Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...	Prescription Only Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...
Administration
Subcutaneous. Learn more.	Subcutaneous . Learn more.
Dosing
Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.	70 mg once monthly or 140 mg once monthly (for some patients). Learn more.
Latin Shorthand
240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.	70 mg/mo or 140 mg/mo. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$5. Learn more.
Annual Cap
$4900. Learn more.	Patient specific maximum benefit.. Learn more.
Assistance Expiration
12 months. Learn more.	Calendar year. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.	The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.	CGRP Antagonist . Learn more.
Special Populations
What is the Pregnancy Exposure Registry for EMGALITY? The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus. How can pregnant women enroll in the Pregnancy Exposure Registry? Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com. What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Are there any known risks associated with the use of EMGALITY during pregnancy? There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development. Can EMGALITY be used during lactation? There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition. Is EMGALITY safe for pediatric use? Safety and effectiveness in pediatric patients have not been established. Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients? Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.	Is it safe to use AIMOVIG during pregnancy? There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women. Is there any clinical consideration for women with migraine during pregnancy? Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. What animal data is available for AIMOVIG use during pregnancy? In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly. Is it safe to use AIMOVIG while breastfeeding? There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition. Is AIMOVIG safe for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is AIMOVIG safe for use in geriatric patients? Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Emgality®(galcanezumab-gnlm)

Aimovig®(erenumab-aooe)

Prescription Only

Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...

Prescription Only

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Subcutaneous . Learn more.

Dosing

Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.

70 mg once monthly or 140 mg once monthly (for some patients). Learn more.

Latin Shorthand

240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.

70 mg/mo or 140 mg/mo. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

$5. Learn more.

Annual Cap

$4900. Learn more.

Patient specific maximum benefit.. Learn more.

Assistance Expiration

12 months. Learn more.

Calendar year. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.

The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.

Mechanism of Actions (MoA)

CGRP Antagonist. Learn more.

CGRP Antagonist . Learn more.

Special Populations

What is the Pregnancy Exposure Registry for EMGALITY?

The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.

How can pregnant women enroll in the Pregnancy Exposure Registry?

Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.

What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Are there any known risks associated with the use of EMGALITY during pregnancy?

There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.

Can EMGALITY be used during lactation?

There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.

Is EMGALITY safe for pediatric use?

Safety and effectiveness in pediatric patients have not been established.

Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?

Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Is it safe to use AIMOVIG during pregnancy?

There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women.

Is there any clinical consideration for women with migraine during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What animal data is available for AIMOVIG use during pregnancy?

In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly.

Is it safe to use AIMOVIG while breastfeeding?

There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition.

Is AIMOVIG safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is AIMOVIG safe for use in geriatric patients?

Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Emgality® Alternatives